BM cellularity, differentials, and FLT3 and C/EBPα mutations for patients treated with quizartinib
| Patient . | Cellularity, Pre . | Blasts, Pre . | Myelocytes and neutrophils, Pre . | Cellularity, D.29 . | Blasts, D.29 . | Myelocytes and neutrophils, D.29 . | FLT3 allelic ratio, Pre . | FLT3 allelic ratio, D.29 . | C/EBPα mutation . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 70% | 15% | 25% | 70% | 7% | 43% | 0.1 | 0.2 | None |
| 2 | 95% | 84% | 8% | 40% | 0% | 83% | 4.1 | 1.6 | TAD* |
| 3 | 80% | 86% | 5% | 60% | 29% | 36% | 0.2 | 0.1 | None |
| 4 | 40% | 71% | 11% | ND | 3% | 83% | 0.3 | 0.2 | None |
| 5 | 90% | 80% | 2% | 50% | 2% | 51% | 4.9 | 3.8 | None |
| 6 | 90% | 87% | 8% | 80% | 1% | 55% | 0.2 | 0.2 | None |
| 7 | 90% | 87% | 6% | 90% | 2% | 75% | 16.4 | 12.9 | None |
| 8 | 90% | 89% | 1% | 60% | 24% | 20% | 4 | 1.5 | None |
| 9 | 50% | 95% | ND | 85% | 2% | 40% | 7 | 13 | None |
| 10 | 60% | 92% | 3% | 80% | 4% | 73% | 3 | 4 | None |
| 11 | 75% | 75% | 12% | 70% | 6% | 53% | 3.7 | 1.3 | None |
| 12 | 70% | 77% | 14% | 85% | 0% | 63% | 0.8 | 1.3 | None |
| 13 | ND | 59% | 15% | 40% | 0% | 66% | 1.3 | 1 | None |
| Mean | 75% | 77% | 9% | 68% | 6% | 57% | 3.5 | 3.2 | |
| 14 | 90% | 85% | 7% | 90% | 59% | 9% | 0.4 | 0.3 | bZIP |
| Patient . | Cellularity, Pre . | Blasts, Pre . | Myelocytes and neutrophils, Pre . | Cellularity, D.29 . | Blasts, D.29 . | Myelocytes and neutrophils, D.29 . | FLT3 allelic ratio, Pre . | FLT3 allelic ratio, D.29 . | C/EBPα mutation . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 70% | 15% | 25% | 70% | 7% | 43% | 0.1 | 0.2 | None |
| 2 | 95% | 84% | 8% | 40% | 0% | 83% | 4.1 | 1.6 | TAD* |
| 3 | 80% | 86% | 5% | 60% | 29% | 36% | 0.2 | 0.1 | None |
| 4 | 40% | 71% | 11% | ND | 3% | 83% | 0.3 | 0.2 | None |
| 5 | 90% | 80% | 2% | 50% | 2% | 51% | 4.9 | 3.8 | None |
| 6 | 90% | 87% | 8% | 80% | 1% | 55% | 0.2 | 0.2 | None |
| 7 | 90% | 87% | 6% | 90% | 2% | 75% | 16.4 | 12.9 | None |
| 8 | 90% | 89% | 1% | 60% | 24% | 20% | 4 | 1.5 | None |
| 9 | 50% | 95% | ND | 85% | 2% | 40% | 7 | 13 | None |
| 10 | 60% | 92% | 3% | 80% | 4% | 73% | 3 | 4 | None |
| 11 | 75% | 75% | 12% | 70% | 6% | 53% | 3.7 | 1.3 | None |
| 12 | 70% | 77% | 14% | 85% | 0% | 63% | 0.8 | 1.3 | None |
| 13 | ND | 59% | 15% | 40% | 0% | 66% | 1.3 | 1 | None |
| Mean | 75% | 77% | 9% | 68% | 6% | 57% | 3.5 | 3.2 | |
| 14 | 90% | 85% | 7% | 90% | 59% | 9% | 0.4 | 0.3 | bZIP |
BM core biopsy samples (decalcified, slide mounted, and stained with H&E) were examined by light microscopy to visually estimate cellularity within 2 weeks prior (Pre) and after 4 weeks of continuous therapy (D.29) with quizartinib. BM aspirates (obtained from the same procedure as the core biopsies) were stained with Wright-Giemsa stain and examined by light microscopy. For each specimen, 100 cells were counted and scored by morphology as blasts, myelocytes, metamyelocytes, bands, or neutrophils and are expressed as a percentage of the total. FLT3 allelic ratios were derived from the aspirate specimens. C/EBPα mutation status was determined as described in “DNA isolation and sequencing.” Mean values are shown for patients 1-13.
The TAD mutation was detectable only at disease progression after 4 months of quizartinib therapy.